heracles - istituto superiore di sanitàold.iss.it/binary/crlp/cont/1_casulli_heracles_fp7... ·...
Post on 13-Jul-2020
5 Views
Preview:
TRANSCRIPT
20/12/2013
1
HERACLES
KICK-OFF meeting 17-18 Dec 2013
The EC launched a SPECIFIC CALL (First Time!!) on the neglected infectious diseases.
20/12/2013
2
• THEME: HEALTH.2013.2.3.4-1: Neglected infectious diseases of Central and Eastern Europe
• FUNDING SCHEME: Collaborative Project (small-scale focused research project).
• THE AIM: establish an integrated approach for the development of preventive, therapeutic and diagnostic tools for NID. This action support innovative, collaborative biomedical research proposals. Focus on one or more viral, bacterial, protozoan, and/or helminthic human diseases.
• EXPECTED IMPACT: new knowledge about the biological mechanisms and pathology of NID.
H.E.R.A.C.L.E.S.
Human cystic Echinoccosis ReseArch in CentraL and Eastern Societies
GA: 602051 1st October, 2013 - 2017
20/12/2013
3
Countries of origin of HERACLES
20/12/2013
4
P. LEGAL NAME ACRONYM TYPE COUNTRY
1 ISTITUTO SUPERIORE DI SANITÀ ISS Research
Institute ITALY
2 UNIVERSITY OF PAVIA UNIPV Hospital
University ITALY
3 AGENCIA ESTATAL CONSEJO SUPERIOR DE
INVESTIGACIONES CIENTÍFICAS CSIC
Research
Institute SPAIN
4 SPITATUL CLINIC COLENTINA BUCURESTI CCHUMFCD Hospital
University ROMANIA
5 HACETTEPE UNIVERSITESI HUSMDR Hospital
University TURKEY
6
HOSPITAL FOR ACTIVE TREATMENT OF
INFECTIOUS AND PARASITIC DISEASES "PROF. I.
KIROV”
SHATIPD Hospital
University BULGARIA
7 MINISTRY OF FOOD AGRICOLTURE AND
LIVESTOCK PVCI
Research
Institute TURKEY
8 ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE
S.R.L.U. ALTA
Service-
provider
company
ITALY
9 VIRCELL S.L. VIRCELL Small Medium
Enterprise SPAIN
20/12/2013
5
Month Items Tentative
Location
2 Kick-Off meeting
(17-18/12/2013) Rome (Italy)
12 2° meeting Ankara (Turkey)
24 3° meeting Bucharest (Romania)
36 4° meeting Sofia (Bulgaria)
48 Final meeting Rome (Italy)
MEETING SCHEDULE
Scheme of HERACLES management
G.A. C.A.
20/12/2013
6
The main OBJECTIVES of HERACLES are:
- Identify by ultrasound screening the population affected by CE;
- Create EE national registry for the surveillance of CE to provide baseline data for risk calculations and to establish a prospective case retrieval;
- Establish a Bio-Bank from animal and human CE patients and related Databases;
- Validate new molecular-based POC-LOC kits for immunological surveillance, rapid diagnosis and follow-up in humans and animals;
- Identify molecular base/s associated with CE response to therapy or lack thereof through host-parasite interplay;
- Increase drug bioavailability in an in vivo model and to synthesize a new enantiomeric drug based on ABZ.
WP1
WP2 WP3
CE ultrasound screeening
EE registry
Host-parasite interplay
BioBank (databases)
new molecular based tools
Enantiomeric drug developing
WP4
Training and dissemination
WP5
Management and IPR
WP6
20/12/2013
7
MANAGEMENT and IPR (WP6)
TRAINING and DISSEMINATION (WP5)
ULTRASOUND SCREENING (WP1)
HERACLES WORKFLOW
VALIDATION of MOLECULAR TOOLS
(WP2)
BIO-BANK (WP2)
COMMERCIAL POC-LOC KIT (WP2)
ANIMAL SAMPLES COLLECTION (WP4)
ABZ BIOAVAILABILITY and ENANTIOMERIC
DRUG SYNTHESIS (WP4)
IN VIVO ANIMAL MODEL (WP4)
HOST-PARASITE INTERPLAY (WP3)
EE REGISTRY (WP1)
HUMAN SAMPLES COLLECTION (WP1)
HOSPITALS NETWORK (WP1)
ULTRASOUND SCREENING and CE NATIONAL REGISTRIES - WP1
Task 1.1: Survey statistical assessment Task 1.2: Ultrasound Survey Task 1.3: Human sample collection Task 1.4: EE registries
20/12/2013
8
NEW MOLECULAR-BASED TOOLS – WP2
Task 2.1: Sample Repository Task 2.2: Database development Task 2.3: Production and testing recombinant antigens Task 2.4: Development of POC-LOC devices
HOST-PARASITE INTERPLAY – WP3
Task 3.1: Genotypic characterization (Parasite) Task 3.2: HLA class I and II polymorphisms (Human) Task 3.3: KIR gene polymorphisms (Human) Task 3.4: HLA-G polymorphism (Human) Task 3.5: Proteomic analysis (Human) Task 3.6: Transcriptome analysis (Parasite)
(parasite virulence vs human immunity)
20/12/2013
9
BIOAVAILABILITY of ABZ and ENANTIOMERIC DRUG SYNTHESIS – WP4
Task 4.1: Animal sample collection Task 4.2: Parasite collection and drug formulations Task 4.3: Experimental design in the animal model Task 4.4: Necropsy and sample collection Task 4.5: Pharmacokinetics and Toxicology Task 4.6: Statistical analysis and new drug synthesis
Infection
Experiments
Drug bioavailability
Parasite viability
Toxicology
TRAINING and DISSEMINATION – WP5
Task 5.1: Dissemination of results a) EU citizens
b) experts c) public health authorities, policy makers
Task 5.2: Training a) staff exchange b) ultrasound on CE, PAIR and related techniques, genotyping c) educational events
Task 5.3: Exploitation of the project results
20/12/2013
10
Task 6.1: Set up of project structure and activities Task 6.2: Administrative Management Task 6.3: IPR Task 6.4: Ethics Management
MANAGEMENT and IPR – WP6
Thank you!
......is growing!
top related